OBJECTIVE： To investigate effectiveness and safety of rh-endostatin in the treatment of keloid. METHODS： Sixty-four keloid patients in Nanchong Central Hospital during Jan. 2015-Jan. 2016 were divided into observation group and control group by random number table， with 32 cases in each group. Both group received fractional CO2 laser treatment. After surgery， control group was given antioxidant drug and antibiotics routinely. Observation group was additionally given Rh-endostatin injection 0.1-0.2 mg/cm2 via keloid body， once a month， for twice， on the basis of control group. Clinical efficacy， symptom score after laser treatment and 2 months after laser treatment， wound healing time， wound pigmentation area and keloid area before and after treatment， the occurrence of ADR were compared between 2 groups. RESULTS： There was no statistical significance in total response rate （93.75％ vs. 87.50％） and the incidence of ADR （15.63％ vs. 12.50％） between observation group and control group （P＞0.05）. There was no statistical significance in symptom score of control group between after laser treatment and after 2 months of treatment （P＞0.05）. The erythema， edema and pigmentation scores of observation group were significantly lower than before treatment and control group， with statistical significance （P＜0.05）； there was no statistical significance in skin itching and burning sensation score between 2 groups （P＞0.05）. The wound incrustation time， decrustation time and wound healing time of observation group were significantly shorter than those of control group， with statistical significance （P＜0.05）. Pigmentation area and keloid area of 2 groups were significantly smaller than before， and the observation group was significantly smaller than the control group， with statistical significance （P＜0.05）. CONCLUSIONS： Rh-endostatin can alleviate erythema， edema， pigmentation and other symptoms effectively， shorten healing time， and inhibit pigmentation and keloid regeneration effectively with good safety.